Science with a different perspective A Danish biopharmaceutical company
Therapeutics

Reversed innovation · Denmark

New purpose
for proven science.

We find new indications for existing technologies — rethinking established medicines to help address unmet medical needs.

Discover our approach Explore our portfolio
Look at what exists.See what it could become.
46markets reached through direct presence and partners
20 + NIcountries covered by the 2026 EU misoprostol approval
2014the beginning of our technology-led story
2026new U.S. patent granted for cluster headache treatment

Our point of view

Innovation doesn’t always start from scratch.

Sometimes the next meaningful advance comes from seeing familiar science differently. Through research, we work relentlessly to improve lives by addressing unmet medical needs. Reversed Innovation is our core value: we transform established products and technologies to address new, previously overlooked or underexplored medical challenges, repurposing proven solutions to make a meaningful difference for patients worldwide.

The story behind reversed innovation
Laboratory and research at AFYX

Research grounded in decades of experience

A patient-focused AFYX therapeutic technology

“How can research be translated into pharmaceutical products?”

Dr. Claus J. Møller-San Pedro, Founder & CEO

What we work on

Focused on needs that matter.

Our work spans specialty pharmaceuticals, repurposed medicines and proprietary technologies across several areas of care.

01 / ONCOLOGY

Head & neck cancer

Nimorazole and technology-led development focused on hypoxic modification in cancer care.

Clinical development
02 / WOMEN’S HEALTH

Labour induction

Low-dose oral misoprostol received approval in 20 European countries and Northern Ireland in May 2026.

EU approval · 2026
03 / NEUROLOGY

Cluster headache

Intranasal ketamine treatment backed by a U.S. patent granted in September 2026.

Patent granted · 2026
04 / PAIN & ADDICTION

Repurposed medicines

Exploring established therapies and formulations for important, underserved needs.

Research & development
Explore products and development

Research & development

A portfolio built to move science forward.

A snapshot of the published AFYX pipeline. Development status and plans can change over time.

AFYX research and development pipeline across head and neck cancer, addiction, labour induction, cluster headache and other indications. Pipeline snapshot from June 2026.
Source: AFYX Therapeutics pipeline, June 2026 Discuss partnering opportunities ↗

A recent milestone

Low-dose oral misoprostol: EU approval

Approved in 20 European countries and Northern Ireland in May 2026 for induction of labour. Use is for qualified healthcare professionals in accordance with approved product information and local clinical guidance.

Read the announcement
AFYX product packaging AFYX product presentation

Local roots. Global partnerships.

From Denmark, reaching patients worldwide.

AFYX reports a presence in 46 global markets, through a combination of direct operations and valued distribution partners.

Meet AFYX and our partners
AFYX Therapeutics global market presence and distribution partners
AFYX Lionheart Pharmaceuticals Inphena Lunatus Cevidra
All partners and collaborations
AFYX scientific research and technology visual

Trusted development

Experience in building biopharma companies.

Dr. Claus J. Møller-San Pedro is AFYX’s CEO. Before AFYX, he co-founded and participated in securing successful initial public offerings for three BioPharma companies: OXiGENE Inc. (OTLC), Genmab A/S (GMAB) and Y-mAbs Therapeutics, Inc. (YMAB).

Meet our management and Board

Our story

Different beginnings.
One shared purpose.

AFYX Therapeutics was established through the 2024 merger of organizations with complementary experience in drug delivery, pain and cancer research, and pharmaceutical development.

2014

AFYX Therapeutics

Development of patented patch technology designed to adhere to wet surfaces.

2015

Lionheart Pharmaceuticals

Focus on treatment approaches for chronic and intermittent cluster headache.

2017

Inphena Pain & Cancer

Research, development and sales of repurposed existing pharmaceuticals.

2024

One AFYX

The combined company brings those capabilities together under reversed innovation.

AFYX team sharing research at a scientific conference
AFYX at an industry conference

In conversation with science

Progress is a shared effort.

We connect with researchers, healthcare professionals and partners to explore better ways to address unmet needs.

The people behind the work

Experience across the life sciences.

Leadership with experience in research, clinical development, company building, finance and commercialization.

Dr. Claus J. Møller-San Pedro

Dr. Claus J. Møller-San Pedro

Founder, CEO & Board Member

Pernille Træholt

Pernille Træholt

VP, Chief Development Officer

Pia Møller-San Pedro

Pia Møller-San Pedro

Board Member & SVP, Chief Operating Officer

Fredrik D. Knudsen

Fredrik D. Knudsen

Senior Financial Director

Michael N. Rimikis

Michael N. Rimikis

VP, Business Development & Medical Network

Board of Directors

Governance shaped by medical, commercial and financial perspectives.

Dr. Ole Baadsgaard · Chairman Dr. Claus J. Møller-San Pedro Pia Møller-San Pedro Søren Kjær

News & updates

Our latest developments.

Company updates, regulatory milestones and partnerships from across the AFYX portfolio.

21 September 2026 · Intellectual property

U.S. patent granted for intranasal ketamine treatment of cluster headache

The United States Patent and Trademark Office issued U.S. Patent No. 12,734,136 to AFYX Therapeutics.

Read the announcement
4 May 2026 · Regulatory

EU approval for low-dose oral misoprostol

Approval for induction of labour in 20 European countries and Northern Ireland.

Read the announcement
22 January 2026 · Partnership

Strategic partnership with Adcock Ingram Critical Care

Distribution partnership for South Africa and Sub-Saharan Africa.

Read the announcement
All company news

For investors & partnersDownload the AFYX non-confidential investor presentation, May 2026.

View presentation ↗

Meet us at Bio-Europe
Cologne, Germany · 9–11 November 2026

Arrange a conversation

Start a conversation

Let’s find a better way forward.

For partnership, investor, media or general enquiries, contact our team in Denmark or Norway.

Email AFYX Call Denmark Contact details

AFYX Therapeutics HQ

Slotsmarken 11, 1.tv.
DK-2970 Hørsholm
Denmark
VAT: 38793594
+45 7174 7174
info@afyxtx.com

AFYX Norway

Gaustadalléen 21
NO-0349 Oslo
Norway
VAT: 922 558 221
+47 2396 7174